CA2865556A1 - Antibody product comprising n specific antibodies - Google Patents

Antibody product comprising n specific antibodies Download PDF

Info

Publication number
CA2865556A1
CA2865556A1 CA2865556A CA2865556A CA2865556A1 CA 2865556 A1 CA2865556 A1 CA 2865556A1 CA 2865556 A CA2865556 A CA 2865556A CA 2865556 A CA2865556 A CA 2865556A CA 2865556 A1 CA2865556 A1 CA 2865556A1
Authority
CA
Canada
Prior art keywords
specific antibodies
antibody
antibody product
content
total
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865556A
Other languages
English (en)
French (fr)
Inventor
Jan WESJOHANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAT MALTA ADVANCED TECHNOLOGIES Ltd
Original Assignee
MAT MALTA ADVANCED TECHNOLOGIES Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAT MALTA ADVANCED TECHNOLOGIES Ltd filed Critical MAT MALTA ADVANCED TECHNOLOGIES Ltd
Publication of CA2865556A1 publication Critical patent/CA2865556A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2865556A 2011-04-05 2012-03-28 Antibody product comprising n specific antibodies Abandoned CA2865556A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011006781A DE102011006781A1 (de) 2011-04-05 2011-04-05 Antikörperprodukt, umfassend n spezifische Antikörper
DE102011006781.7 2011-04-05
PCT/EP2012/055456 WO2012136522A1 (de) 2011-04-05 2012-03-28 Antikörperprodukt, umfassend n spezifische antikörper

Publications (1)

Publication Number Publication Date
CA2865556A1 true CA2865556A1 (en) 2012-10-11

Family

ID=45937295

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865556A Abandoned CA2865556A1 (en) 2011-04-05 2012-03-28 Antibody product comprising n specific antibodies

Country Status (5)

Country Link
US (1) US20140099328A1 (zh-CN)
EP (1) EP2694541A1 (zh-CN)
CA (1) CA2865556A1 (zh-CN)
DE (1) DE102011006781A1 (zh-CN)
WO (1) WO2012136522A1 (zh-CN)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
CN107889490A (zh) 2015-04-17 2018-04-06 维尔茨堡尤利乌斯-马克西米利安大学 抗lps免疫球蛋白治疗的临床应答的预测性生物标志物
WO2020147950A1 (en) 2019-01-16 2020-07-23 Ignova Gmbh Methods of treating fibromyalgia

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748018A (en) * 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
GB9105292D0 (en) * 1991-03-13 1991-04-24 Sandoz Ltd Improvements in or relating to organic compounds
AUPN115095A0 (en) * 1995-02-15 1995-03-09 Butt, Henry Lawrence Analysis of and compositions and methods for the treatment of disease
CZ287989B6 (cs) * 1998-03-20 2001-03-14 Medipharm Cz, S. R. O. Perorální přípravek k prevenci a léčbě infekčních gastroenteritid prasat
WO2001048018A1 (en) * 1999-12-27 2001-07-05 University Of Manitoba Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
WO2006035979A1 (ja) * 2004-09-29 2006-04-06 Asama Chemical Co., Ltd. 乳清タンパク、乳由来の抗体または抗体を含む機能性組成物または食品
WO2009092383A2 (en) * 2008-01-22 2009-07-30 Multimerics Aps Products and methods to prevent infection
EA024697B1 (ru) * 2009-04-27 2016-10-31 Иммурон Лимитед Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени
WO2011036539A1 (en) * 2009-09-23 2011-03-31 Borody Thomas J Therapy for enteric infections
AU2011290478B2 (en) * 2010-08-17 2014-11-13 Hadasit Medical Research Services & Development Limited Anti-LPS enriched immunoglobulin preparation for use in treatment and/or prophylaxis of a pathologic disorder
US20130273074A1 (en) * 2010-10-04 2013-10-17 Immuron Limited Methods and Compositions Using Anti-LPS Ligands for the Treatment and Prevention of Inflammatory Disorders
DE102011006809A1 (de) * 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten

Also Published As

Publication number Publication date
DE102011006781A1 (de) 2012-10-11
US20140099328A1 (en) 2014-04-10
EP2694541A1 (de) 2014-02-12
WO2012136522A1 (de) 2012-10-11

Similar Documents

Publication Publication Date Title
WO2012122410A3 (en) Platform for rapid development of applications
WO2014074607A3 (en) Skills endorsements
IL261900A (en) Humanized antibodies against liv-1, preparations containing them and their uses
IL252154A0 (en) Antibodies against dr5, preparations containing them and their uses
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
WO2012088483A3 (en) Application reporting in an application-selectable user interface
IL233934B (en) Antibodies to cd47, preparations containing them and their uses
WO2013083999A3 (en) Nano-enhanced elastomers
WO2011005799A3 (en) Rna containing modified nucleotides and use thereof in vaccines
WO2012006487A3 (en) Fluoropolymer blend and articles thereof
IL226383B (en) Antibodies against ccl20, preparations containing them and their uses
WO2009061535A3 (en) Content item pricing
IL225460B (en) Antibodies that bind to p4d12191, preparations containing them and their uses
WO2010089411A3 (en) Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2012014076A3 (en) Liver organoid, uses thereof and culture method for obtaining them
WO2011089183A3 (en) Anticoagulant antidotes
GB2513732A (en) Methods and compositions for sample identification
WO2010138861A3 (en) Contextual content targeting
EP2571982A4 (en) ANTIGEN-SPECIFIC TREGS AND CORRESPONDING COMPOSITIONS, METHODS AND SYSTEMS
WO2011148305A3 (en) Systems and methods for providing a social mashup in a content provider environment
CA138917S (en) Beverage package
WO2012078383A3 (en) Evaluation assistant for online discussion
WO2012149002A3 (en) Food container behavior modification system and method
WO2010136104A3 (en) Anti-dandruff agents
CA2865556A1 (en) Antibody product comprising n specific antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140826

FZDE Discontinued

Effective date: 20170420